These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

110 related items for PubMed ID: 10927030

  • 1. Antioxidant activity of the monoamine oxidase B inhibitor lazabemide.
    Mason RP, Olmstead EG, Jacob RF.
    Biochem Pharmacol; 2000 Sep 01; 60(5):709-16. PubMed ID: 10927030
    [Abstract] [Full Text] [Related]

  • 2. In vitro effects on monoamine uptake and release by the reversible monoamine oxidase-B inhibitors lazabemide and N-(2-aminoethyl)-p-chlorobenzamide: a comparison with L-deprenyl.
    Bondiolotti GP, Galva MD, Villa F, Sciaba L, Picotti GB.
    Biochem Pharmacol; 1995 Jun 29; 50(1):97-102. PubMed ID: 7605351
    [Abstract] [Full Text] [Related]

  • 3. Lazabemide (Ro 19-6327), a reversible and highly sensitive MAO-B inhibitor: preclinical and clinical findings.
    Henriot S, Kuhn C, Kettler R, Da Prada M.
    J Neural Transm Suppl; 1994 Jun 29; 41():321-5. PubMed ID: 7931245
    [Abstract] [Full Text] [Related]

  • 4. Investigation on the structure of the active site of monoamine oxidase-B by affinity labeling with the selective inhibitor lazabemide and by site-directed mutagenesis.
    Cesura AM, Gottowik J, Lahm HW, Lang G, Imhof R, Malherbe P, Röthlisberger U, Da Prada M.
    Eur J Biochem; 1996 Mar 15; 236(3):996-1002. PubMed ID: 8665924
    [Abstract] [Full Text] [Related]

  • 5. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition.
    Zheng H, Gal S, Weiner LM, Bar-Am O, Warshawsky A, Fridkin M, Youdim MB.
    J Neurochem; 2005 Oct 15; 95(1):68-78. PubMed ID: 16181413
    [Abstract] [Full Text] [Related]

  • 6. The Design and Evaluation of an l-Dopa-Lazabemide Prodrug for the Treatment of Parkinson's Disease.
    Hoon M, Petzer JP, Viljoen F, Petzer A.
    Molecules; 2017 Nov 27; 22(12):. PubMed ID: 29186917
    [Abstract] [Full Text] [Related]

  • 7. Design, synthesis and biological evaluation of lazabemide derivatives as inhibitors of monoamine oxidase.
    Zhou S, Chen G, Huang G.
    Bioorg Med Chem; 2018 Sep 15; 26(17):4863-4870. PubMed ID: 30143367
    [Abstract] [Full Text] [Related]

  • 8. Pharmacodynamics of lazabemide, a reversible and selective inhibitor of monoamine oxidase B.
    Holford NH, Guentert TW, Dingemanse J, Kettler R.
    Br J Clin Pharmacol; 1994 Jun 15; 37(6):553-7. PubMed ID: 7917773
    [Abstract] [Full Text] [Related]

  • 9. Combined treatment with MAO-A inhibitor and MAO-B inhibitor increases extracellular noradrenaline levels more than MAO-A inhibitor alone through increases in beta-phenylethylamine.
    Kitaichi Y, Inoue T, Nakagawa S, Boku S, Izumi T, Koyama T.
    Eur J Pharmacol; 2010 Jul 10; 637(1-3):77-82. PubMed ID: 20406628
    [Abstract] [Full Text] [Related]

  • 10. MAO-B inhibition by a single dose of l-deprenyl or lazabemide does not prevent neuronal damage following focal cerebral ischaemia in rats.
    Jolkkonen J, Kauppinen R, Nyman L, Haapalinna A, Sivenius J.
    Pharmacol Toxicol; 2000 Nov 10; 87(5):242-5. PubMed ID: 11129505
    [Abstract] [Full Text] [Related]

  • 11. Increased monoamine oxidase B activity in plaque-associated astrocytes of Alzheimer brains revealed by quantitative enzyme radioautography.
    Saura J, Luque JM, Cesura AM, Da Prada M, Chan-Palay V, Huber G, Löffler J, Richards JG.
    Neuroscience; 1994 Sep 10; 62(1):15-30. PubMed ID: 7816197
    [Abstract] [Full Text] [Related]

  • 12. Effect of aging on lazabemide binding, monoamine oxidase activity and monoamine metabolites in human frontal cortex.
    Galva MD, Bondiolotti GP, Olasmaa M, Picotti GB.
    J Neural Transm Gen Sect; 1995 Sep 10; 101(1-3):83-94. PubMed ID: 8695059
    [Abstract] [Full Text] [Related]

  • 13. Pharmacokinetics and pharmacodynamics of single and multiple doses of the MAO-B inhibitor lazabemide in healthy subjects.
    Dingemanse J, Wood N, Jorga K, Kettler R.
    Br J Clin Pharmacol; 1997 Jan 10; 43(1):41-7. PubMed ID: 9056051
    [Abstract] [Full Text] [Related]

  • 14. Ro 19-6327, a reversible and highly selective monoamine, oxidase B inhibitor: a novel tool to explore the MAO-B function in humans.
    Haefely WE, Kettler R, Keller HH, Da Prada M.
    Adv Neurol; 1990 Jan 10; 53():505-12. PubMed ID: 2122653
    [No Abstract] [Full Text] [Related]

  • 15. Lazabemide for the treatment of Alzheimer's disease: rationale and therapeutic perspectives.
    Cesura AM, Borroni E, Gottowik J, Kuhn C, Malherbe P, Martin J, Richards JG.
    Adv Neurol; 1999 Jan 10; 80():521-8. PubMed ID: 10410766
    [No Abstract] [Full Text] [Related]

  • 16. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline.
    Kupsch A, Sautter J, Götz ME, Breithaupt W, Schwarz J, Youdim MB, Riederer P, Gerlach M, Oertel WH.
    J Neural Transm (Vienna); 2001 Jan 10; 108(8-9):985-1009. PubMed ID: 11716151
    [Abstract] [Full Text] [Related]

  • 17. Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain.
    Ng KP, Pascoal TA, Mathotaarachchi S, Therriault J, Kang MS, Shin M, Guiot MC, Guo Q, Harada R, Comley RA, Massarweh G, Soucy JP, Okamura N, Gauthier S, Rosa-Neto P.
    Alzheimers Res Ther; 2017 Mar 31; 9(1):25. PubMed ID: 28359327
    [Abstract] [Full Text] [Related]

  • 18. Safety study of lazabemide (Ro19-6327), a new MAO-B inhibitor, on cardiac arrhythmias and blood pressure of patients with Parkinson's disease.
    Narabayashi H, Yamaguchi T, Sugi K, Mitamura H, Mizuno Y, Nakashima M.
    Clin Neuropharmacol; 1999 Mar 31; 22(6):340-6. PubMed ID: 10626094
    [Abstract] [Full Text] [Related]

  • 19. Genetic elevation of monoamine oxidase levels in dopaminergic PC12 cells results in increased free radical damage and sensitivity to MPTP.
    Wei Q, Yeung M, Jurma OP, Andersen JK.
    J Neurosci Res; 1996 Dec 15; 46(6):666-73. PubMed ID: 8978500
    [Abstract] [Full Text] [Related]

  • 20. Inhibition of monoamine oxidase modulates the behaviour of semicarbazide-sensitive amine oxidase (SSAO).
    Fitzgerald DH, Tipton KF.
    J Neural Transm (Vienna); 2002 Mar 15; 109(3):251-65. PubMed ID: 11956949
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.